RecruitingNCT06929910

Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.

Evaluation of Systemic Therapy and the Effectiveness of Circulating Tumor DNA (ctDNA) Assays in Monitoring Treatment Response in Patients With Metastatic Cancer Undergoing K4Care Testing

Sponsor

Gene Solutions

Enrollment

200 participants

Start Date

Apr 9, 2025

Study Type

OBSERVATIONAL

Conditions

Metastatic Cancers

Summary

The goal of this observational study is to investigate the real-world treatment landscape of patients with metastatic cancer and determine the role of ctDNA in monitoring treatment response in patients with metastatic cancer who have undergone K4Care testing

Eligibility

Inclusion Criteria4

Pathological and imaging confirmation of metastatic or progressive stage IV cancer.
Consent to the use of their clinical data.
Diagnosis of one of the following common solid tumor types: lung, colorectal, breast, gastric, or cancer of unknown primary origin.
Prior K4Care testing to identify tumor tissue (FFPE) mutations and consent to the use of their sequencing data.